Is NAVB or SYRS more profitable?

Navidea Biopharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Syros Pharmaceuticals N/A -3,369.56% -97.04%

Is GNCA or SYRS more profitable?

Genocea Biosciences' return on equity of -182.88% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Genocea Biosciences N/A -182.88% -62.76% Syros Pharmaceuticals N/A -3,369.56% -97.04%

Is SYRS or PXMD more profitable?

PaxMedica's return on equity of -3,167.89% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Syros Pharmaceuticals N/A -3,369.56% -97.04% PaxMedica N/A -3,167.89% -560.35%

Do analysts recommend ADTX or SYRS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Syros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, ADTX or SYRS?

Aditxt has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.39 -$41.71M -$100.79 thousand N/A Syros Pharmaceuticals $386K 0.03 -$164.57M -$3.03 N/A

Is ARDS or SYRS more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Syros Pharmaceuticals N/A -3,369.56% -97.04%

Does the media favor ARDS or SYRS?

In the previous week, Aridis Pharmaceuticals and Aridis Pharmaceuticals both had 1 articles in the media. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aridis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Syros Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Syros Pharmaceuticals (SYRS) Competitors

$0.0004 0.00 (0.00%)

As of 09/3/2026 02:21 PM Eastern

Compare

SYRS vs. NAVB, GNCA, PXMD, ADTX, and ARDS

Should you buy Syros Pharmaceuticals stock or one of its competitors? Syros Pharmaceuticals's main competitors and comparable companies include Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), PaxMedica (PXMD), Aditxt (ADTX), and Aridis Pharmaceuticals (ARDS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Syros Pharmaceuticals compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

Navidea Biopharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Syros Pharmaceuticals had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Syros Pharmaceuticals and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Syros Pharmaceuticals	Neutral

Summary

Navidea Biopharmaceuticals beats Syros Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Genocea Biosciences' return on equity of -182.88% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	-182.88%	-62.76%
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

Genocea Biosciences has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.91M	0.00	-$33.20M	-$0.61	N/A
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

In the previous week, Syros Pharmaceuticals had 1 more articles in the media than Genocea Biosciences. MarketBeat recorded 1 mentions for Syros Pharmaceuticals and 0 mentions for Genocea Biosciences. Genocea Biosciences' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genocea Biosciences	Neutral
Syros Pharmaceuticals	Neutral

Summary

Genocea Biosciences beats Syros Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to PaxMedica?

Syros Pharmaceuticals (NASDAQ:SYRS) and PaxMedica (NASDAQ:PXMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

PaxMedica's return on equity of -3,167.89% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%
PaxMedica	N/A	-3,167.89%	-560.35%

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market.

PaxMedica has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A

In the previous week, Syros Pharmaceuticals had 1 more articles in the media than PaxMedica. MarketBeat recorded 1 mentions for Syros Pharmaceuticals and 0 mentions for PaxMedica. Syros Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company	Overall Sentiment
Syros Pharmaceuticals	Neutral
PaxMedica	Neutral

Summary

Syros Pharmaceuticals beats PaxMedica on 7 of the 10 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Syros Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

Aditxt has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Syros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

15.5% of Aditxt shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aditxt has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.39	-$41.71M	-$100.79 thousand	N/A
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

In the previous week, Syros Pharmaceuticals had 1 more articles in the media than Aditxt. MarketBeat recorded 1 mentions for Syros Pharmaceuticals and 0 mentions for Aditxt. Aditxt's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aditxt	Neutral
Syros Pharmaceuticals	Neutral

Summary

Syros Pharmaceuticals beats Aditxt on 8 of the 13 factors compared between the two stocks.

How does Syros Pharmaceuticals compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Aridis Pharmaceuticals has a beta of 49.66, indicating that its share price is 4,866% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market.

Aridis Pharmaceuticals has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	$0.31	0.00
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Aridis Pharmaceuticals and Aridis Pharmaceuticals both had 1 articles in the media. Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aridis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syros Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aridis Pharmaceuticals beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Syros Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYRS vs. The Competition

Export

Metric	Syros Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	0.00	787.27	273.29	25.25
Price / Sales	0.03	754.88	623.67	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.00	12.33	12.92	6.14
Net Income	-$164.57M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.60%	0.60%	-0.27%
1 Month Performance	N/A	6.96%	5.72%	0.68%
1 Year Performance	N/A	9.45%	25.33%	14.84%

Syros Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYRS Syros Pharmaceuticals	N/A	$0.00 flat	N/A	-63.6%	$11K	$386K	N/A	120	Gap Up
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10
GNCA Genocea Biosciences	N/A	N/A	N/A	N/A	$6K	$1.91M	N/A	70
PXMD PaxMedica	N/A	$0.00 flat	N/A	N/A	$6K	N/A	N/A	2	High Trading Volume
ADTX Aditxt	0.174 of 5 stars	$0.01 -23.8%	N/A	-100.0%	$5K	$14.34K	N/A	60	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYRS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Syros Pharmaceuticals (SYRS) Competitors

SYRS vs. NAVB, GNCA, PXMD, ADTX, and ARDS

How does Syros Pharmaceuticals compare to Navidea Biopharmaceuticals?

Summary

How does Syros Pharmaceuticals compare to Genocea Biosciences?

Summary

How does Syros Pharmaceuticals compare to PaxMedica?

Summary

How does Syros Pharmaceuticals compare to Aditxt?

Summary

How does Syros Pharmaceuticals compare to Aridis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRS vs. The Competition

Syros Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Syros Pharmaceuticals (SYRS) Competitors

SYRS vs. NAVB, GNCA, PXMD, ADTX, and ARDS

How does Syros Pharmaceuticals compare to Navidea Biopharmaceuticals?

Which has more risk and volatility, NAVB or SYRS?

Is NAVB or SYRS more profitable?

Which has stronger valuation & earnings, NAVB or SYRS?

Do institutionals & insiders hold more shares of NAVB or SYRS?

Does the media prefer NAVB or SYRS?

Summary

How does Syros Pharmaceuticals compare to Genocea Biosciences?

Do insiders and institutionals have more ownership in GNCA or SYRS?

Is GNCA or SYRS more profitable?

Which has higher valuation and earnings, GNCA or SYRS?

Which has more risk & volatility, GNCA or SYRS?

Does the media refer more to GNCA or SYRS?

Summary

How does Syros Pharmaceuticals compare to PaxMedica?

Is SYRS or PXMD more profitable?

Do institutionals & insiders have more ownership in SYRS or PXMD?

Which has more risk and volatility, SYRS or PXMD?

Which has higher valuation & earnings, SYRS or PXMD?

Does the media refer more to SYRS or PXMD?

Summary

How does Syros Pharmaceuticals compare to Aditxt?

Is ADTX or SYRS more profitable?

Which has more risk and volatility, ADTX or SYRS?

Do analysts recommend ADTX or SYRS?

Do institutionals and insiders have more ownership in ADTX or SYRS?

Which has stronger earnings and valuation, ADTX or SYRS?

Does the media favor ADTX or SYRS?

Summary

How does Syros Pharmaceuticals compare to Aridis Pharmaceuticals?

Which has more risk and volatility, ARDS or SYRS?

Which has higher valuation and earnings, ARDS or SYRS?

Is ARDS or SYRS more profitable?

Do insiders & institutionals believe in ARDS or SYRS?

Does the media favor ARDS or SYRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRS vs. The Competition

Syros Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools